Glioblastoma Multiforme (GBM) is the most common and aggressive form of intracranial tumors with poor prognosis. In recent years, tumor immunotherapy has been an attractive strategy for a variety of tumors. Currently, most immunotherapies take advantage of the adaptive anti-tumor immunity, such as cytotoxic T cells. However, the predominant accumulation of tumor-associated microglia/macrophages (TAMs) results in limited success of these strategies in the glioblastoma. To improve the immunotherapeutic efficacy for GBM, it is detrimental to understand the role of TAM in glioblastoma immunosuppressive microenvironment. In this review, we will discuss the roles of CD47-SIRPα axis in TAMs infiltration and activities and the promising effects of targeting this axis on the activation of both innate and adaptive antitumor immunity in glioblastoma.

胶质母细胞瘤（GBM）是颅内肿瘤的最常见和侵袭性形式，预后较差。近年来，肿瘤免疫疗法已成为多种肿瘤的诱人策略。当前，大多数免疫疗法利用诸如细胞毒性T细胞的适应性抗肿瘤免疫。但是，肿瘤相关的小胶质细胞/巨噬细胞（TAM）的主要积累导致这些策略在胶质母细胞瘤中的成功有限。为了提高GBM的免疫治疗效果，了解TAM在胶质母细胞瘤免疫抑制微环境中的作用是有害的。在这篇综述中，我们将讨论CD47-SIRPα轴在TAM浸润和活动中的作用，以及以该轴为靶点对胶质母细胞瘤固有免疫和适应性抗肿瘤免疫的激活的有希望的作用。